Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Placebo-Controlled, Double Blind, Ascending Dose Cohort Study to Evaluate Safety and Efficacy of EB-001 IM Injections in Reducing Musculoskeletal Pain in Subjects Undergoing Elective Augmentation Mammoplasty (Breast Augmentation)

Trial Profile

Phase 2 Placebo-Controlled, Double Blind, Ascending Dose Cohort Study to Evaluate Safety and Efficacy of EB-001 IM Injections in Reducing Musculoskeletal Pain in Subjects Undergoing Elective Augmentation Mammoplasty (Breast Augmentation)

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2018

At a glance

  • Drugs Botulinum toxin E (Primary)
  • Indications Musculoskeletal pain
  • Focus Registrational; Therapeutic Use
  • Acronyms LANTERN-1
  • Sponsors Bonti
  • Most Recent Events

    • 28 Aug 2018 Status changed from active, no longer recruiting to completed.
    • 25 Apr 2018 According to a Bonti media release, descriptions of this trial will be presented at the American Society for Aesthetic Plastic Surgery (ASAPS) The Aesthetic Meeting 2018.
    • 16 Apr 2018 Planned End Date changed from 30 Apr 2018 to 30 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top